Evidence map›Paper›PMID 29626277›Full record

ArticleJournal of gastrointestinal cancer2019

Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal Cancer.

Hisham K Dabbous, Yosry Abd El-Rahman Mohamed, Runia F El-Folly, Mohamed D El-Talkawy, Hani E Seddik, Dina Johar, Mohammed A Sarhan

Abstract readEvaluation Study
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Hisham K DabbousTropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Yosry Abd El-Rahman MohamedHepatogastroenterology and Tropical Medicine Department, Theodor Bilharz Research Institute, Cairo, Egypt.
Runia F El-FollyTropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Mohamed D El-TalkawyHepatogastroenterology and Tropical Medicine Department, Theodor Bilharz Research Institute, Cairo, Egypt.
Hani E SeddikHepatogastroenterology and Tropical Medicine Department, Theodor Bilharz Research Institute, Cairo, Egypt.
Dina JoharDepartment of Biochemistry and Nutrition, Faculty of Women for Arts, Sciences and Education, Ain Shams University, Cairo, Egypt. dinajohar@gmail.com.ORCID http://orcid.org/0000-0003-0866-9959
Mohammed A SarhanCenter of Excellence of Gastrointestinal Inflammation and Immunology Research (CEGIIR), Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Ain Shams University · EGTheodor Bilharz Research Institute · EGUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInvasive colonoscopy is the gold standard for patients at risk for colorectal cancer. However, the need for non-invasive and specific markers is required.

objectiveTo evaluate the sensitivity of the glycolytic pyruvate kinase isoenzyme type M2 dimer (M2PK) as a diagnostic biomarker for colorectal cancer (CRC) and adenomatous colorectal polyps (CRP) screening.

designCase-control. PATIENTS: Twenty patients with CRC, 20 patients with CRP (lack criteria for colonic cancer by biopsy), and 20 normal subjects. OUTCOME: Complete blood count (CBC), erythrocyte sedimentation rate (ESR), tumor markers: carcino embryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), fecal occult blood test (FOBT), and fecal M2PK. Pelvic and abdominal ultrasound (US), colonoscopy, and a histopathological examination.

resultsOnly weight loss and cachexia were significantly associated with CRC than CRP or control groups. M2PK was the most sensitive and specific test in differentiating CRC from CRP and the control subjects (sensitivity = 75%, specificity = 100%). LIMITATIONS: (1) The selection of cases for three well-matched groups, as to perform colonoscopy in well-prepared cases and conditions. (2) Replicates in more than 20 cases for confirmation at the expense of enrolling new patients. (3) The cost associated with tumor markers analysis.

conclusionFecal M2PK can be used as a precolonoscopy screening test for CRC patients, and is superior to other tumor markers, and in indicating the progress of colorectal adenomas > 1 cm. Thus being cost-effective and easy-to-perform test, it is a feasible tool to preselect patients who require colonoscopy.

Indexed as

Adenomatous PolypsAdultAgedBiomarkers, TumorCase-Control StudiesColonoscopyColorectal NeoplasmsEarly Detection of CancerFecesFemaleFollow-Up StudiesHumansMaleMiddle AgedOccult BloodPrognosisBiomarkers, TumorPyruvate KinaseColorectal cancerColorectal polypEgyptFecal occult blood testMarkerPatients

Identifiers

PMID29626277
OpenAlexW2796049966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.